Revisiting vitamin B6 metabolism: The emerging role of pyridoxal reductase in the pyridoxal 5'-phosphate salvage pathway.

Vitamin B6 and the Immunity in Kidney Transplant Recipients

Pyridoxal 5'-phosphate (PLP), the coenzyme form of vitamin B6, is indispensable for diverse metabolic processes, especially amino acid metabolism. In mammals, PLP is primarily synthesized via a salvage pathway involving pyridoxal kinase (PLK), pyridoxine/pyridoxamine 5'-phosphate oxidase (PNPO), and pyridoxal phosphate phosphatase (PLPP). However, recent evidence suggests the presence of additional, yet unidentified, enzymatic contributors to this pathway. Here, we identify aldo-keto reductase family 1 member C (AKR1C) isozymes as previously unrecognized enzymes involved in vitamin B6 metabolism. We demonstrate that AKR1Cs catalyze two novel reactions: an NADPH-dependent pyridoxal reductase (PLR) activity that converts pyridoxal (PL) to pyridoxine (PN), and an NADP+-dependent pyridoxal dehydrogenase (PLD) activity that oxidizes PL to 4-pyridoxolactone (4-PLA). Both reactions occur under physiological conditions and significantly impact intracellular vitamin B6 vitamer profiles. Moreover, we show that elevated PL levels suppress AKR1C activities toward non-B6 substrates, indicating reciprocal cross-talk between vitamin B6 metabolism and other AKR1C-dependent metabolic processes. This study expands the current framework of mammalian vitamin B6 metabolism, highlighting AKR1Cs as metabolic hubs with broad regulatory implications.

Be well: A potential role for vitamin B in COVID-19

In this review it has been pointed out that vitamin B6 and its vitamers can be involved in many interactions with a number of drugs, as well as with the actions of various endocrines and neurotransmitters. Nutritional deficiencies, especially of vitamins and proteins, can affect the manner in which drugs undergo biotransformation, and thereby may also modify the therapeutic efficacy of certain drugs. The differences between nutritional vitamin B6 deficiency and the hereditary disorder producing pyridoxine dependency are discussed. In addition to a pyridoxine deficiency being able to adversely affect drug actions, the improper supplementation with vitamin B6 can in some instances also adversely affect drug efficacy. A decrease by pyridoxine in the efficacy of levodopa used in the treatment of Parkinsonism is an example. The interrelationships and enzymatic interconversions among pyridoxine vitamers, both phosphorylated and non-phosphorylated, are briefly discussed, particularly regarding their pharmacokinetic properties. The ways in which the normal biochemical functions of vitamin B6 may be interfered with by various drugs are reviewed. (1) The chronic administration of isoniazid for the prevention or treatment of tuberculosis can produce peripheral neuropathy which can be prevented by the concurrent administration of pyridoxine. An acute toxic overdose of isoniazid causes generalized convulsions, and the intravenous administration of pyridoxine hydrochloride will prevent or stop these seizures. (2) The acute ingestion of excessive monosodium glutamate will, in some individuals, cause a group of symptoms including among others headache, weakness, stiffness, and heartburn, collectively known as the 'Chinese Restaurant Syndrome.' These symptoms can be prevented by prior supplementation with vitamin B6. The beneficial effect is ascribed to the correction of a deficiency in the activity of glutamic oxaloacetic transaminase, an enzyme that is dependent on pyridoxal phosphate. Some interesting relationships are pointed out between vitamin B6, picolinic acid, and zinc. It is postulated that the intestinal absorption of zinc is facilitated by picolinic acid, a metabolite of tryptophan. The derivation of picolinic acid from tryptophan depends on the action of the enzyme kynureninase, which is dependent on pyridoxal phosphate; therefore, the adequate absorption of zinc is indirectly dependent on an adequate supply of vitamin B6. The formation of pyridoxal phosphate, on the other hand, appears to be indirectly dependent on Zn2++ which activates pyridoxal kinase.(ABSTRACT TRUNCATED AT 400 WORDS)

Water-soluble vitamins like B3 (nicotinamide), B6 (pyridoxine), and B9 (folic acid) are of utmost importance in human health and disease, as they are involved in numerous critical metabolic reactions. Not surprisingly, deficiencies of these vitamins have been linked to various disease states. Unfortunately, not much is known about the physiological levels of B6 vitamers and vitamin B3 in an ethnically isolated group (such as an Emirati population), as well as their relationship with obesity. The aim of the present study was to quantify various B6 vitamers, as well as B3, in the plasma of obese and healthy Emirati populations and to examine their correlation with obesity. A sensitive and robust HPLC-MS/MS-based method was developed for the simultaneous quantitation of five physiologically relevant forms of vitamin B6, namely pyridoxal, pyridoxine, pyridoxamine, pyridoxamine phosphate, and pyridoxal phosphate, as well as nicotinamide, in human plasma. This method was used to quantify the concentrations of these vitamers in the plasma of 57 healthy and 57 obese Emirati volunteers. Our analysis showed that the plasma concentrations of nicotinamide, pyridoxal, and pyridoxamine phosphate in the obese Emirati population were significantly higher than those in healthy volunteers (p < 0.0001, p = 0.0006, and p = 0.002, respectively). No significant differences were observed for the plasma concentrations of pyridoxine and pyridoxal phosphate. Furthermore, the concentrations of some of these vitamers in healthy Emirati volunteers were significantly different than those published in the literature for Western populations, such as American and European volunteers. This initial study underscores the need to quantify micronutrients in distinct ethnic groups, as well as people suffering from chronic metabolic disorders.

Pyridoxal 5'-phosphate in plasma: source, protein-binding, and cellular transport.

In various organisms, the coenzyme form of vitamin B6, pyridoxal phosphate (PLP), is synthesized from pyridoxine phosphate (PNP). Control of PNP levels is crucial for metabolic homeostasis because PNP has the potential to inhibit PLP-dependent enzymes and proteins. Although the only known pathway for PNP metabolism in Escherichia coli involves oxidation by PNP oxidase, we detected a strong PNP phosphatase activity in E. coli cell lysate. To identify the unknown PNP phosphatase(s), we performed a multicopy suppressor screening using the E. coli serA pdxH strain, which displays PNP-dependent conditional lethality. The results showed that overexpression of the yigL gene, encoding a putative sugar phosphatase, effectively alleviated the PNP toxicity. Biochemical analysis revealed that YigL has strong phosphatase activity against PNP. A yigL mutant exhibited decreased PNP phosphatase activity, elevated intracellular PNP concentrations, and increased PNP sensitivity, highlighting the important role of YigL in PNP homeostasis. YigL also shows reactivity with PLP. The phosphatase activity of PLP in E. coli cell lysate was significantly reduced by mutation of yigL and nearly abolished by additional mutation of ybhA, which encodes putative PLP phosphatase. These results underscore the important contribution of YigL, in combination with YbhA, as a primary enzyme in the dephosphorylation of both PNP and PLP in E. coli.IMPORTANCEPyridoxine phosphate (PNP) metabolism is critical for both vitamin B6 homeostasis and cellular metabolism. In Escherichia coli, oxidation of PNP was the only known mechanism for controlling PNP levels. This study uncovered a novel phosphatase-mediated mechanism for PNP homeostasis. Multicopy suppressor screening, kinetic analysis of the enzyme, and knockout/overexpression studies identified YigL as a key PNP phosphatase that contributes to PNP homeostasis when facing elevated PNP concentrations in E. coli. This study also revealed a significant contribution of YigL, in combination with YbhA, to PLP metabolism, shedding light on the mechanisms of vitamin B6 regulation in bacteria.

The pyridoxal 5'-phosphate (PLP)-binding protein (PLPBP) plays an important role in vitamin B6 homeostasis. Loss of this protein in organisms such as Escherichia coli and humans disrupts the vitamin B6 pool and induces intracellular accumulation of pyridoxine 5'-phosphate (PNP), which is normally undetectable in wild-type cells. This accumulated PNP could affect diverse metabolic systems through the inhibition of some PLP-dependent enzymes. In this study, we investigated the as-yet-unclear mechanism of intracellular accumulation of PNP due to the loss of PLPBP protein encoded by yggS in E. coli. Genetic studies using several PLPBP-deficient strains of E. coli lacking a known enzyme(s) in the de novo or salvage pathways of vitamin B6, including pyridoxine (amine) 5'-phosphate oxidase (PNPO), PNP synthase, pyridoxal kinase, and pyridoxal reductase, demonstrated that neither the flux from the de novo pathway nor the salvage pathway solely contributed to the PNP accumulation caused by the PLPBP mutation. Studies of the strains lacking both PLPBP and PNPO suggested that PNP shares the same pool with PMP, and showed that PNP levels are impacted by PMP levels and vice versa. Here, we show that disruption of PLPBP perturbs PMP homeostasis, which may result in PNP accumulation in the PLPBP-deficient strains. IMPORTANCE A PLP-binding protein (PLPBP) from the conserved COG0325 family has recently been recognized as a key player in vitamin B6 homeostasis in various organisms. Loss of PLPBP disrupts vitamin B6 homeostasis and perturbs diverse metabolisms, including amino acid and α-keto acid metabolism. Accumulation of PNP is a characteristic phenotype of PLPBP deficiency and is suggested to be a potential cause of the pleiotropic effects, but the mechanism of this accumulation has been poorly understood. In this study, we show that fluxes for PNP synthesis/metabolism are not responsible for the accumulation of PNP. Our results indicate that PLPBP is involved in the homeostasis of pyridoxamine 5'-phosphate, and that its disruption may lead to the accumulation of PNP in PLPBP deficiency.

Background and objectives: Riboflavin in the form flavin mononucleotide (FMN) acts as a cofactor for the pyridoxine phosphate oxidase required to generate pyridoxal 5′-phosphate (PLP), the active form of vitamin B6 in tissues. Few human studies have investigated this metabolic interaction between riboflavin and vitamin B6. The primary objective of this study was to examine the response of plasma PLP to riboflavin supplementation in individuals with the MTHFR 677TT genotype. A secondary objective was to consider whether the dose of riboflavin (1.6 mg/d vs. 10 mg/d) affects the PLP response. Methods: Data from four randomised controlled trials (RCTs) of riboflavin supplementation previously conducted at this centre were accessed to identify 209 participants of 19–60 years meeting the inclusion criteria (≤60 years, MTHFR 677TT genotype, not taking a vitamin B6 supplement). In the original RCTs, participants were randomly assigned to receive a placebo (n = 85) or 1.6 mg/d of riboflavin (n = 87) for 16 weeks. In one trial only, a higher riboflavin dose, 10 mg/d (n = 37), was administered. Plasma PLP was measured via reversed phase HPLC with fluorescence detection. Riboflavin status was assessed using the functional assay, erythrocyte glutathione reductase activation coefficient (EGRac). Results: riboflavin supplementation resulted in a decrease (p < 0.001) in the mean EGRac values, from 1.34 (1.32, 1.37) to 1.21 (1.19, 1.22). Correspondingly, PLP increased (p = 0.027), an effect driven by those with a sub-optimal riboflavin status at baseline (EGRac > 1.26), whereby PLP increased by 5.2 nmol/L, from 44.9 (40.3, 49.4) to 50.1 (44.6, 55.6) nmol/L (p = 0.042), while with the optimal baseline riboflavin (EGRac ≤ 1.26), there was no significant PLP response to the intervention. Although 10 mg/d vs. 1.6 mg/d of riboflavin resulted in a greater EGRac response (p = 0.012), there was no significant effect of riboflavin dose on the PLP response. Discussion: These results provide randomised trial evidence that optimising riboflavin status leads to an increase in plasma PLP, confirming the metabolic dependency of vitamin B6 on FMN. The findings indicate that riboflavin intake may need to be considered when setting dietary recommendations for vitamin B6 in adults. Further work is needed to explore the impact of the common MTHFR C677T polymorphism of the interrelationship of these B vitamins.

Vitamin B6 metabolism in microbes and approaches for fermentative production

Validated UPLC-MS/MS method for the analysis of vitamin B6 pyridoxal 5́-phosphate, pyridoxal, pyridoxine, pyridoxamine, and pyridoxic acid in human cerebrospinal fluid

Biosynthesis of vitamin B6 is essential for all living cells. Most organisms use the pyridoxal 5’-phosphate (PLP) synthase complex to synthesize the cofactor form, PLP, from the three substrates ribose 5-phosphate (R5P), glyceraldehyde 3-phosphate (G3P) and ammonia. PLP synthase complex is a glutamine amidotransferase (GATase) class I, consisting of 12 Pdx1 and 12 Pdx2 subunits. Pdx1 is responsible for the PLP synthesis and Pdx2 is the glutaminase that hydrolyses glutamine to produce ammonia, which is transfered to the Pdx1 active site. In this PhD Thesis, studying Pdx1 and Pdx2 proteins from the human parasite Plasmodium falciparum and from the rodent parasite Plasmodium berghei gave important insights into the assembly, activation and substrate tunneling of the PLP synthase complex. Electron microscopy analyses showed that association of the PLP synthase and glutaminase subunits was random, suggesting a non cooperative mechanism independent of neighboring Pdx1 binding sites to be occupied by Pdx2. Complex assembly is critical for glutamine hydrolysis by Pdx2, although the presence of an ammonia acceptor in the Pdx1 active site did neither enhance the Pdx1/Pdx2 interaction nor the catalytic rate of Pdx2 in vitro, as tested by biophysical and kinetic experiments. In particular, the PLP synthase complex does not show allosteric activation by R5P or glutamine binding that would result in synchronization of the glutaminase and PLP synthesis reactions. Therefore, the Pdx1/Pdx2 interaction is enough to stimulate glutamine hydrolysis. A particular motivation of this Thesis was to crystallize the PLP synthase complex from the malaria causing parasite, P. falciparum, for the potential use of the 3D structure in drug design. However, the complex assembled into fibers in vitro, induced by the Pdx1 subunit, making the crystallization trials of this enzyme impossible. A chimeric complex formed by Pdx1 from P. berghei and Pdx2 from P. falciparum proved to be a catalytically active system, suitable for structural studies of the plasmodial complex. Crystal structure of this enzyme complex gave two major advances in the understanding how prokaryotic and eukaryotic PLP synthase complexes resemble each other or differ in protein interaction and activation. Variations at the Pdx1/Pdx2 interface occur through insertion sequences in eukaryotic systems, notably in the plasmodial PLP synthase complex by the loop 95-111 in Pdx2. Activation of the glutaminase is highly conserved in both systems. The process entails reorganization of structural regions at the Pdx1/Pdx2 interface through stabilization of alpha-N and the oxyanion hole region. Activation of the PLP synthase requires a helical segment, named alpha-2’, for sugar binding. The helix is observed in two alternative positions in the Pdx1/Pdx2 and Pdx1-R5P structures: an open conformation to allow the entrance of the substrate and a closed conformation oriented towards R5P, sequestering the substrate in the catalytic center. The pentose substrate is bound in the P1 site to the catalytic Lys84 via a Schiff base with the ribose C1 atom. GATases are characterized by two separate active sites for glutamine hydrolysis and enzyme-specific metabolite syntheses. Previously, ammonia transfer between two catalytic centers was proposed to occur by flexible methionine residues within a transient tunnel in Pdx1. The plasmodial proteins show an ammonia tunnel distict from bacterial orthologs as some of the residues lining the passage are exchanged. Biochemical analysis confirmed that the (beta/alpha)8 -barrel of Pdx1 passes the reactive ammonia produced in Pdx2 to Pdx1 active site, assigning function of key residues for the ammonia channeling. The differences between eukaryotic and prokaryotic systems provide insight into PLP synthase complex regulation, which may be exploitable in drug design for the treatment of malaria.

Vitamin B6 (vitB6) is a generic term that comprises six interconvertible pyridine compounds. These vitB6 compounds (also called vitamers) are pyridoxine (PN), pyridoxamine (PM), pyridoxal (PL) and their 5′-phosphorylated forms pyridoxine 5′-phosphate (PNP), pyridoxamine 5′-phosphate (PMP) and pyridoxal 5′-phosphate (PLP). VitB6 is an essential nutrient for all living organisms, but only microorganisms and plants can carry out de novo synthesis of this vitamin. Other organisms obtain vitB6 from dietary sources and interconvert its different forms according to their needs via a biochemical pathway known as the salvage pathway. PLP is the biologically active form of vitB6 which is important for maintaining the biochemical homeostasis of the body. In the human body, PLP serves as a cofactor for more than 140 enzymatic reactions, mainly associated with synthesis, degradation and interconversion of amino acids and neurotransmitter metabolism. PLP-dependent enzymes are also involved in various physiological processes, including biologically active amine biosynthesis, lipid metabolism, heme synthesis, nucleic acid synthesis, protein and polyamine synthesis and several other metabolic pathways. PLP is an important vitamer for normal brain function since it is required as a coenzyme for the synthesis of several neurotransmitters including D-serine, D-aspartate, L-glutamate, glycine, γ-aminobutyric acid (GABA), serotonin, epinephrine, norepinephrine, histamine and dopamine. Intracellular levels of PLP are tightly regulated and conditions that disrupt this homeostatic regulation can cause disease. In humans, genetic and dietary (intake of high doses of vitB6) conditions leading to increase in PLP levels is known to cause motor and sensory neuropathies. Deficiency of PLP in the cell is also implicated in several diseases, the most notable example of which are the vitB6-dependent epileptic encephalopathies. VitB6-dependent epileptic encephalopathies (B6EEs) are a clinically and genetically heterogeneous group of rare inherited metabolic disorders. These debilitating conditions are characterized by recurrent seizures in the prenatal, neonatal, or postnatal period, which are typically resistant to conventional anticonvulsant treatment but are well-controlled by the administration of PN or PLP. In addition to seizures, children affected with B6EEs may also suffer from developmental and/or intellectual disabilities, along with structural brain abnormalities. Five main types of B6EEs are known to date, these are: PN-dependent epilepsy due to ALDH7A1 (antiquitin) deficiency (PDE-ALDH7A1) (MIM: 266100), hyperprolinemia type 2 (MIM: 239500), PLP-dependent epilepsy due to PNPO deficiency (MIM: 610090), hypophosphatasia (MIM: 241500) and PLPBP deficiency (MIM: 617290). This chapter provides a review of vitB6 and its different vitamers, their absorption and metabolic pathways in the human body, the diverse physiological roles of vitB6, PLP homeostasis and its importance for human health. Finally, the chapter reviews the inherited neurological disorders affecting PLP homeostasis with a special focus on vitB6-dependent epileptic encephalopathies (B6EEs), their different subtypes, the pathophysiological mechanism underlying each type, clinical and biochemical features and current treatment strategies.

Vitamin B6 includes six water-soluble vitamers: pyridoxal (PL), pyridoxamine (PM), pyridoxine (PN), and their phosphorylated forms. Pyridoxal 5′-phosphate (PLP) is an important cofactor for many metabolic enzymes. Several lines of evidence demonstrate that blood levels of PLP are significantly lower in patients with inflammation than in control subjects and that vitamin B6 has anti-inflammatory effects, with therapeutic potential for a variety of inflammatory diseases. Although one of our group previously demonstrated that PL inhibits the NF-κB pathway, the molecular mechanism by which vitamin B6 suppresses inflammation is not well understood. Here, we showed that both PL and PLP suppressed the expression of cytokine genes in macrophages by inhibiting Toll-like receptor (TLR)-mediated TAK1 phosphorylation and the subsequent NF-κB and JNK activation. Furthermore, PL and PLP abolished NLRP3-dependent caspase-1 processing and the subsequent secretion of mature IL-1β and IL-18 in LPS-primed macrophages. In contrast, PM and PN had little effect on IL-1β production. PLP, but not PL, markedly reduced the production of mitochondrial reactive oxygen species (ROS) in peritoneal macrophages. Importantly, PL and PLP reduced IL-1β production induced by LPS and ATP, or by LPS alone, in mice. Moreover, PL and PLP protected mice from lethal endotoxic shock. Collectively, these findings reveal novel anti-inflammatory activities for vitamin B6 and suggest its potential for preventing inflammatory diseases driven by the NLRP3 inflammasome.

Pyridoxal 5'-phosphate (PLP) is an essential cofactor for organisms in all three domains of life. Despite the central role of PLP, many aspects of vitamin B6 metabolism, including its integration with other biological pathways, are not fully understood. In this study, we examined the metabolic perturbations caused by the vitamin B6 antagonist 4-deoxypyridoxine (dPN) in a ptsJ mutant of Salmonella enterica serovar Typhimurium LT2. Our data suggest that PdxK (pyridoxal/pyridoxine/pyridoxamine kinase [EC 2.7.1.35]) phosphorylates dPN to 4-deoxypyridoxine 5'-phosphate (dPNP), which in turn can compromise the de novo biosynthesis of PLP. The data are consistent with the hypothesis that accumulated dPNP inhibits GlyA (serine hydroxymethyltransferase [EC 2.1.2.1]) and/or GcvP (glycine decarboxylase [EC 1.4.4.2]), two PLP-dependent enzymes involved in the generation of one-carbon units. Our data suggest that this inhibition leads to reduced flux to coenzyme A (CoA) precursors and subsequently decreased synthesis of CoA and thiamine. This study uncovers a link between vitamin B6 metabolism and the biosynthesis of CoA and thiamine, highlighting the integration of biochemical pathways in microbes. IMPORTANCE PLP is a ubiquitous cofactor required by enzymes in diverse metabolic networks. The data presented here expand our understanding of the toxic effects of dPN, a vitamin B6 antagonist that is often used to mimic vitamin B6 deficiency and to study PLP-dependent enzyme kinetics. In addition to de novo PLP biosynthesis, we define a metabolic connection between vitamin B6 metabolism and synthesis of thiamine and CoA. This work provides a foundation for the use of dPN to study vitamin B6 metabolism in other organisms.